Nivolumab plus chemotherapy does not improve PFS in EGFR-mutated NSCLC
CheckMate 722 trial fails to meet its primary endpoint in patients with cancer progressing on one or two prior lines of EGFR tyrosine-kinase inhibitors
Serplulimab plus chemotherapy prolongs progression-free survival in PD-L1-positive oesophageal squamous cell carcinoma
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
Test for gut microbiota predicts survival in patients receiving an immune checkpoint inhibitor
An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions
Combining liquid biopsy technologies may help improve tumour monitoring
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Dynamic immunoediting of tumours may hold the clue to effective treatment with immunotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Should cancer therapy be tailored based on receptor tyrosine kinase alterations?
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy
Molecular cancer early detection and prevention - an attainable goal?
Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers
Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies